Seegene announced the launch of the Global Million Clinical Study (GMCS) in July, an initiative with the goal of improving understanding of clinical diagnostics worldwide by gathering one million global test results to evaluate the clinical value of comprehensive syndromic PCR testing. Medical Laboratory Observer (MLO) spoke with Seegene about the project and its goals, how the information uncovered will be used, what this means for laboratory workflows and infectious disease testing practices, and next steps.

MLO: Could you tell us more about the Global Million Clinical Study, and what distinguishes it from previous studies evaluating syndromic PCR testing?

Seegene: The Global Million Clinical Study, or GMCS, is a large-scale real-world evidence initiative designed to generate and analyze one million clinical test results to evaluate the importance and clinical value of comprehensive syndromic PCR testing. The project is currently in its early phase, with participation and operational details being discussed with healthcare institutions and Seegene’s global network. Its initial research areas include respiratory, gastrointestinal, and STI/HPV-related infections.

What distinguishes GMCS is its scale and approach. It aims to bring together real-world clinical data from diverse healthcare settings and evaluate comprehensive testing across multiple major infectious disease areas. By analyzing large-scale clinical data, GMCS seeks to assess whether comprehensive PCR testing that detects multiple major causative pathogens can provide meaningful information beyond conventional targeted testing, including a broader understanding of pathogen prevalence, co-detection patterns, and infection trends.

Through this approach, GMCS aims to build scientific evidence supporting a more comprehensive, disease-focused approach to infectious disease testing, one that looks beyond a limited number of presumed pathogens and considers the broader range of potential infectious causes associated with a clinical syndrome.

Seegene plans to use STAgora, its PCR testing data analytics and statistical platform, to systematically analyze the clinical data generated through GMCS, including pathogen prevalence and infection trends across disease types and geographic regions. Ultimately, GMCS aims to build the scientific evidence needed to support more comprehensive, evidence-based infectious disease testing strategies and contribute to scientific discussions surrounding future testing standards.

MLO: What gaps in current infectious disease testing practices does Seegene hope GMCS will help address?

Seegene: Infectious disease testing practices vary considerably across countries and healthcare systems. Even for the same disease, the pathogens included in testing panels, recommended testing protocols, and reimbursement policies can differ. In many settings, testing also remains focused on a limited number of pathogens or a single category of pathogens, even though different pathogens can cause similar symptoms and multiple pathogens may be detected concurrently.

These realities can make it difficult to capture the broader range of infectious causes associated with a clinical syndrome. A testing approach focused only on selected pathogens may provide useful answers for those specific targets, but may not reveal other potentially relevant pathogens or broader co-detection and epidemiological patterns.

Through GMCS, Seegene aims to generate large-scale real-world clinical evidence on pathogen prevalence, previously undetected pathogens, co-detection patterns, genotypes, and regional and seasonal epidemiological trends. Rather than presupposing the value of comprehensive testing, GMCS seeks to build the scientific evidence needed to assess where broader, disease-focused testing may provide meaningful additional clinical information.

MLO: GMCS will generate real-world data across healthcare institutions and geographic regions. What types of insights do you expect this large-scale dataset to reveal that may not be captured through conventional testing approaches?

Seegene: Conventional targeted testing provides information about the pathogens included in a specific test, but it may not capture the broader pathogen patterns associated with a clinical syndrome. GMCS aims to generate large-scale real-world data that can provide insights into previously undetected pathogens, co-detection patterns, genotype distributions, and regional and seasonal epidemiological trends.

The value of GMCS lies not only in the scale of the dataset, but also in the ability to examine these patterns across diverse populations, healthcare institutions, geographic regions, and time periods. By analyzing these patterns at scale, GMCS aims to assess whether broader, disease-focused testing can provide meaningful additional information beyond conventional testing approaches and help build the scientific evidence needed to inform future testing strategies.

MLO: The study initially will focus on reproductive tract, respiratory tract, and gastrointestinal tract infections. How will the findings from these disease areas be evaluated to determine whether a comprehensive testing strategy could improve clinical decision-making?

Seegene: GMCS aims to examine the additional information generated through comprehensive testing within each disease area. Depending on the disease group, analyses may include pathogen prevalence, co-detection patterns, identification of previously undetected pathogens, genotype distributions, seasonal trends, and differences across populations and geographic regions.

These findings will help assess where comprehensive syndromic testing may provide information that is not captured when testing is limited to a small number of pathogens or a single category of pathogens. For example, identifying different pathogens associated with similar symptoms or detecting multiple pathogens simultaneously may provide a more complete picture of the potential infectious causes associated with a clinical syndrome.

GMCS is still in its early phase, and detailed study protocols and evaluation criteria are currently being developed. The study is designed to generate the real-world evidence needed to assess where and how broader, disease-focused testing may provide meaningful clinical value, rather than assuming such benefits in advance.

MLO: How could the evidence generated through GMCS ultimately influence infectious disease testing guidelines, laboratory workflows, or testing standards across different healthcare systems?

Seegene: GMCS is intended to generate a large body of real-world clinical evidence that can contribute to broader scientific discussions about how infectious diseases should be tested. Today, testing recommendations and laboratory practices can differ substantially by country, healthcare system, and disease area, reflecting differences in epidemiology, healthcare infrastructure, clinical practice, laboratory capacity, and reimbursement systems.

By generating and analyzing data across different disease areas, institutions, geographic regions, and populations, GMCS may help identify where comprehensive syndromic testing provides meaningful additional information and where more targeted approaches may remain appropriate.

Through GMCS, Seegene aims to build a scientific evidence base that can contribute to discussions within the clinical laboratory and medical communities and, over time, help inform disease-specific testing strategies and the development of future testing standards.

Any practical application of these findings would need to take local healthcare environments into account. Rather than proposing a single testing model for every healthcare system, GMCS aims to provide evidence that can support more informed testing strategies appropriate to different clinical and healthcare settings.

MLO: What are the next steps for GMCS? Are there plans to expand the study beyond reproductive tract, respiratory tract, and gastrointestinal tract infections?

Seegene: GMCS is currently in its early phase. Seegene is continuing to develop the study framework and participation structure for the initial disease areas through discussions with its global network and participating healthcare institutions.

At this stage, the focus is on establishing a robust foundation for generating and analyzing real-world clinical testing data across respiratory, gastrointestinal, and STI/HPV-related infections. Details regarding participating institutions, geographic scope, study timelines, and the sequencing of individual research areas are still being discussed and finalized.

In the longer term, the GMCS framework could potentially be applied to additional disease areas where comprehensive pathogen information may provide meaningful additional insights. However, no specific expansion plans beyond the current disease areas have been finalized at this stage.